NASDAQ · SLS
SELLAS Life Sciences Group, Inc.
$10.16-$0.23 (-2.17%)
SELLAS Life Sciences Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 36.05% below the high.
Loading market information…
NASDAQ · IVVD · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Invivyd, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.39% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Invivyd, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.11. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Invivyd, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:10 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 15, 2025 |
| -$0.14-250.0% vs estimate |
| $11.30M-35.41% vs estimate |
| Q4 2024 | Mar 20, 2025 | -$0.15+40.0% vs estimate | $13.82M-59.88% vs estimate |
|---|
| Q3 2024 | Nov 14, 2024 | -$0.51-54.55% vs estimate | $9.30M-32.93% vs estimate |
|---|
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$10.16-$0.23 (-2.17%)
SELLAS Life Sciences Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 36.05% below the high.
$5.23-$0.05 (-0.95%)
OmniAb, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.68% below the high.
€11.40-€0.06 (-0.52%)
Genfit S.A.’s quoted price sits in the upper half of its reported 52-week range, 26.36% below the high.
$3.30-$0.10 (-2.8%)
C4 Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.17% below the high.
$6.09+$0.10 (+1.67%)
Orchestra BioMed Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.31% below the high.
$2.52+$0.03 (+1.2%)
Protara Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.77% below the high.
$1.22-$0.04 (-3.17%)
Codexis, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.06% below the high.
$3.18$0.00 (0.0%)
Insight Molecular Diagnostics Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.63% below the high.
